GlycoNex, Inc. (4168) Stock Price & Analysis
4168 Stock Chart & Stats
- Day’s Range
- TWD 18.30 - TWD 19.95
- 52-Week Range
- TWD 18.30 - TWD 30.00
- Previous Close
- TWD 20.30
- Volume
- N/A
- Average Volume (3M)
- 83.03K
- Market Cap
- TWD 2.24B
- Enterprise Value
- TWD 2.79B
- Total Cash (Recent Filing)
- TWD 567.78M
- Total Debt (Recent Filing)
- TWD 480.20M
- Price to Earnings (P/E)
- ―
- Beta
- 0.38
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Aug 05, 2013
- Dividend Yield
- N/A
GlycoNex, Inc. News
4168 FAQ
What was GlycoNex, Inc.’s price range in the past 12 months?
What is GlycoNex, Inc.’s market cap?
When is GlycoNex, Inc.’s upcoming earnings report date?
How were GlycoNex, Inc.’s earnings last quarter?
Is GlycoNex, Inc. overvalued?
Does GlycoNex, Inc. pay dividends?
What is GlycoNex, Inc.’s EPS estimate?
How many shares outstanding does GlycoNex, Inc. have?
What happened to GlycoNex, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GlycoNex, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
GlycoNex, Inc.
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Mei-Chun Yang
- Employees
- 25
- Website
- www.glyconex.com.tw
- Address
- No. 97, Xintai 5th Road, New Taipei City, NWT, 22175, TW
GlycoNex, Inc. (4168) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |

